E-DRUG: Organizations contest the constitutionality of the Brazilian IP Law
----------------------------------------------------
Mechanism for the granting of patents known as "pipeline" patents violates
the Federal Constitution
On November 28th, the National Federation of Pharmacists (FENAFAR), on behalf of the Brazilian Network for the Integration of Peoples (Rebrip), presented to the General Attorney of the Republic, Mr. Antônio Fernando Barros e Silva e Souza, evidence that demonstrates the nconstitutionality of two articles of the Brazilian Industrial Property Law (Law 9.279/96). According to the authors of the case, articles 230 and 231 of Law n^o. 9.279, that created the patent granting mechanism known as the "pipeline", violate the constitutional principles that impose the supremacy of society's interest and the pursuit of the country's technological and economic development over intellectual property protections (art. 5, XIX). They argue that the granting of pipeline patents also violates the society's acquired right (art. 5, XXXVI); implied due legal process (art. 5, LIV) and the principle of equal treatment before the law (art. 5, caput).
The pipeline mechanism is an institution created by the Industrial
Property Law that allowed the filling of patents in technological
fields that, prior to 1996, had not yet been granted in Brazil. The
mechanism made it possible to obtain patent protections for
pharmaceutical and food products (among other products). The requests
for patents via the pipeline mechanism are only subject to a formal
analysis and they follow the terms of the patent granted in foreign
countries. They are not submitted to a technical evaluation of the
product's ability to meet patentability requirements - novelty,
inventiveness and industrial application - conducted by the Brazilian
patent office, the National Institute of Industrial Property (INPI in
Portuguese). In total, 1 182 patents were filed under the pipeline
mechanism, many of which are for essential medicines used in the
treatment of HIV/AIDS and leukemia, for example. Many of the products
for which patents had been granted through this mechanism were already
in public domain prior to 1996.
A study elaborated by economists calculated the hypothetical financial
losses caused by the adoption of the pipeline mechanism in the case of
government purchases of five anti-retroviral drugs (ARVs), during the
period 2001-2007. The results show that, due to the granting of
unmerited patent protections for these medicines, the Brazilian state
paid an additional US$ 420 million, when prices paid were compared to
the World Health Organisation's minimum prices, and an extra US$ 519
million, when compared to the minimum prices of Doctors Without
Borders (MSF) for the ARVs.
In the opinion of Cristina Pimenta, General Coordinator of the
Brazilian Interdisciplinary AIDS Organisation (ABIA), the organisation
currently coordinating the Rebrip's Working Group on Intellectual
Property, "instead of contributing to the development of the country
and serving public interest, the pipeline mechanism only serves as an
obstacle to universal access and gratuity of treatment for people with
HIV/AIDS". FENAFAR's president, Célia Chaves, adds, "no gain has been
made by this concession - neither for the national pharmaceutical
industry and sector, nor for the population in general. All were
harmed by pipeline patents".
Rebrip and FENAFAR hope to have the current case approved by the
General Attorney of the Republic, so that it will be sent to the
Federal Supreme Court in the form of a direct action of
unconstitutionality.
Examples of pipeline patents:
Efavirenz, a medicine for which a compulsory license was recently
issued, is protected by a patent granted through the pipeline
mechanism. In other words, when the patent of this drug was filed in
Brazil, it no longer met the novelty requirement, as the information
on the invention had already been published abroad five years earlier.
This active ingredient could have been produced in Brazil, as it was
in India.
Other medicines that are fundamental for curbing the HIV/AIDS
epidemic, such as lopinavir/ritonavir, abacavir, nelfinavir and
amprenavir, also were protected by the pipeline mechanism, and as
such, were withdrawn from public domain without any evaluation of its
importance in terms of the country's interests. Furthermore, the
medicine for cancer - imatinib or Glivec (brand name) - was also
protected by the pipeline mechanism. This drug, used to treat people
living with Chronic Myeloid Leukemia, currently costs R$ 10 000,000
(ten thousand Brasilian reals) per month, per patient.
Gabriela Chaves
gabriela@abiaids.org.br